Compared with patients with epilepsy, migraineurs tend to suffer more from psychological difficulties, according to a study published in Journal of Multidisciplinary Healthcare.
Compared with patients with epilepsy, migraineurs tend to suffer more from psychological difficulties, according to a study published in Journal of Multidisciplinary Healthcare.
Migraine is the second leading cause of “years lost due to disability” worldwide and affects roughly 10% to 18% of the population, imposing significant costs to both patients and health systems.
Although migraine is categorized by a severe headache and sometimes aura, epilepsy manifests as unprovoked seizures and can cause psychological and psychiatric complications. Epilepsy is also considered to be associated with migraine and with other somatic disorders such as cardiovascular diseases and diabetes.
“It is important to assess the impact of brain disorders on the patient’s life to help physicians better determine treatment outcomes and monitor the disease course, although there is no exact method to be used for this purpose,” the authors wrote.
To compare psychological difficulties among individuals with prevalent disabling conditions, the researchers conducted a cross-sectional study where 240 migraineurs and 210 individuals with epilepsy completed the Psychosocial Factors Relevant to Brain Disorders in Europe (PARADISE-24) questionnaire.
All participants were recruited from the Isfahan Neurosciences Research Center in Iran between January and April 2020 and were over the age of 18. Questions included in PARADISE-24 are answered on a 3-point scale (none = 0, some = 1, a lot = 2), with high scores indicating greater psychosocial difficulties due to brain disorders. Demographic data in addition to disease characteristics (severity of headache, frequency of seizures, etc) were also collected.
Analyses revealed:
“Patients with migraine suffer from a wide range of psychological difficulties such as depression, poor sleep, sexual dysfunction, anxiety, and impaired quality of life, each of which requires a specific questionnaire or instrument to be assessed,” the researchers wrote. One advantage of the PARADISE questionnaire is its ability to assess various psychological aspects at once.
Epilepsy is also associated with psychological problems like depression, anxiety, memory disfunction, and stigma. The disease accounts for the highest age-standardized disability-adjusted life years (DALYs) in both sexes (0.7% of total DALYs).
Because the study was conducted in a single center and did not include quality of life measurements, the researchers recommended that multicentric studies, including an evaluation of other aspects of both diseases, be carried out.
The findings could guide physicians to consider psychological well-being in migraineurs, the authors concluded.
Reference
Mirmosayyeb O, Shaygannejad V, Ghajarzadeh M. Comparison of psychological difficulties in patients with migraine and epilepsy using PARADISE-24 questionnaire. J Multidiscip Healthc. Published online July 10, 2020. doi:10.2147/JMDH.S260056
Optimizing Episodic Migraine Care: ACP’s Latest Treatment Guidance
February 3rd 2025With historical data showing migraine to be underdiagnosed and undertreated, new guidance from the American College of Physicians (ACP) encompasses 3 recommendations on treating episodic migraine in adult patients in the outpatient setting.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen
Super-Refractory Status Epilepticus Linked With Unknown Etiologies, High Mortality Rates
September 23rd 2023Patients treated for more than 28 days had a higher chance of status epilepticus cessation, but also a high risk of moderate to severe disability at discharge, according to one study.
Read More